Does orlistat work?

Orlistat is a medicine which can help you to lose weight if you are overweight or obese.One way to help with weight loss is to reduce the amount of fat in your diet. Orlistat works by interfering with the way that fat is digested and absorbed into the body.



Studies have shown that, on average, orlistat, plus a weight-reducing diet and exercise, causes more weight loss than a weight-reducing diet and exercise alone. Some people lose 10% or more of their body weight within six months with the help of orlistat. In others, it is less effective,


Doctors usually calculate whether you are underweight, in the 'ideal' weight range, overweight or obese based on your BMI or Body Mass Index. You can work out your BMI from our BMI calculator.If you are overweight or obese. Orlistat works by blocking chemicals (enzymes) in your gut which digest fat. Nearly a third of the fat that you eat is blocked by orlistat. The undigested fat is not absorbed into your body and is passed out with your stools (faeces). The normal dose is one capsule - 120 mg, three times a day with each meal. However, you do not need to take one if there is no fat in the meal or if you miss a meal.



Studies have shown that, on average, orlistat, plus a weight-reducing diet and exercise, causes more weight loss than a weight-reducing diet and exercise alone. Some people lose 10% or more of their body weight within six months with the help of orlistat. In others, it is less effective.One reason why orlistat may not work is that you may think that you can relax your weight-reducing diet, and the orlistat will 'do it all'. This is not true. In order to lose weight you still have to eat less and exercise regularly. Remember, orlistat prevents only some of the fat that you eat from being absorbed (just under a third). But, if you do not keep to a healthy weight-reducing diet, and you eat more fat (chocolates, cakes, etc), the extra fat that you eat will easily cancel out the effect of the orlistat.


Check here: Orlistat Manufacturer Supplier Factory

Social media:
https://www.facebook.com/Cmoapi-114510347044359/
https://www.pinterest.com/cmoapibiotech/boards/

free html5 templates

Reference

1. Barbier P, Schneider F (1987). "Syntheses of tetrahydrolipstatin and absolute configuration of tetrahydrolipstatin and lipstatin". Helvetica Chimica Acta. 70 (1): 196–202. doi:10.1002/hlca.19870700124.
2. Pommier A, Pons M, Kocienski P (1995). "The first total synthesis of (−)-lipstatin". Journal of Organic Chemistry. 60 (22): 7334–7339. doi:10.1021/jo00127a045.
 3.Padwal R, Li SK, Lau DC (2004). Padwal RS (ed.). "Long-term pharmacotherapy for obesity and overweight". Cochrane Database Syst Rev (3): CD004094. doi:10.1002/14651858.CD004094.pub2. PMID 15266516.
4. Gillies, CL; Abrams, KR; Lambert, PC; Cooper, NJ; Sutton, AJ; Hsu, RT; Khunti, K (10 February 2007). "Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis". BMJ (Clinical Research Ed.). 334 (7588): 299. doi:10.1136/bmj.39063.689375.55. PMC 1796695. PMID 17237299.